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Abstract Integrins are the major family of receptors involved 
in the adhesive interactions of cells with extracellular matrix 
macromolecules. Although it is known that integrins can exist in 
active or inactive states, the molecular mechanisms by which 
integrin activity is modulated are poorly understood. A novel 
anti-integrin monoclonal antibody, 12G10, that enhances cr5fll- 
fibronectin interactions has been identified. 12G10 binds to the 
/31 subunit and appears to recognise a region of the subunit that 
contains the epitopes of several previously described activating or 
inhibitory monoclonal antibodies. However, unlike other activat- 
ing anti-p1 antibodies, the binding of 12GlO to (u5pl is increased 
in the presence of ligands (fibronectin fragment or RGD peptide). 
This is the first report for the pl integrin family of an antibody 
that recognises a ligand-induced binding site, and further empha- 
sises the functional importance of a specific region of the fil 
subunit in regulating integrin-ligand interactions. 
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1. Introduction 
Many cell-cell and cell-matrix interactions are mediated by 
members of the integrin superfamily of cell-surface receptors. 
Integrins are a,/3 heterodimers that have been classified into 
eight different groups according to the identity of their p sub- 
unit. The Bl family is the principal group of cell-matrix recep- 
tors [l-3]. 
A general property of integrins is that they can exist in active 
or inactive states; ligand recognition requires that the integrin 
be in the activated state [l]. Ligand recognition has been shown 
to cause a conformational change in integrins, leading to the 
exposure of neo-epitopes known as ligand-induced binding 
sites (LIBS) [4,5]. A number of monoclonal antibodies (mAbs) 
have been described that can activate integrins directly, a subset 
of these are also anti-LIBS antibodies [5]. 
The extracellular matrix glycoprotein fibronectin has served 
as a prototype substrate for the study of integrinligand inter- 
actions and several regions of the molecule have been shown 
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Abbreviations: LIBS, ligand-induced binding site(s); CCBD, central cell 
binding domain of fibronectin; mAb, monoclonal antibody; kDa, 
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CCBD; HBSS, Hank’s balanced salt solution; PBS, phosphate-buffered 
saline; BSA, bovine serum albumin; ELISA, enzyme-linked immuno- 
sorbent assay; ABTS, 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic 
acid); SD., standard deviation. 
to be responsible for its adhesive activity. One domain that is 
recognised by a wide variety of cell types lies close to the centre 
of the fibronectin subunit and contains the tripeptide RGD as 
a key active site [6,7]. The integrin a5pl is the major receptor 
for this central cell-binding domain (CCBD) and is expressed 
on many cell types. Here we have identified a novel anti-/?1 
mAb that stimulates a5/31-fibronectin interactions and also has 
the characteristics of an anti-LIBS antibody. 
2. Materials and methods 
2.1. Materials 
Rat mAbs 16 and 13 recognising the human a5 and /?I integrin 
subunits respectively, were produced and purified as previously de- 
scribed [8]. Mouse anti-human pl integrin mAbs JBlB and K20 were 
purchased from Serotec (Oxford, UK), and The Binding Site (Birming- 
ham, UK), respectively. Mouse mAbs TS2/16 and 8A2 against the 
human PI subunit were gifts from F. Sanchez-Madrid (Hospital de la 
Princesa, Madrid, Spain) and N. Kovach (University of Washington, 
Seattle, USA), respectively. All antibodies were used as purified IgG, 
with the exception of 8A2 (ascites). An 80-kDa fragment of fibronectin 
containing the CCBD was purified from a trypsin digest of plasma 
fibronectin as described [9]. A recombinant fragment of fibronectin 
(H/120) that lacks the CCBD was produced as previously described 
[lo]. The synthetic peptides GRGDS and GRDGS were synthesised 
using Fastmoc chemistry on an Applied Biosystems 431A peptide syn- 
thesiser and purified as described previously [11,12] 
2.2. Production of mAb 12GIO 
Methods were based on those previously described [13]. Briefly, 
BALBlc mice were immunised twice subcutaneously with -200 pg of 
purified /?l integrins from HT-1080 cells (see below) in the presence of 
RIBI adjuvant (Universal Biologicals, London, UK). Three days before 
sacrificing, mice were injected intraperitoneally with HT-1080 integrins 
without adjuvant. Spleens were removed and fused with X63-Ag8.653 
myeloma cells. Hybridomas were screened by ELISA against the immu- 
nogen. Positive hybridomas were cloned by limiting dilution, and fur- 
ther characterised by Western blotting under non-reducing conditions. 
One clone, 12Gl0, was identified as an anti-/?1 mAb because it reacted 
with thepI subunit in Western blots. 12GlO IgG was purified from the 
medium of serum-free culture supernatants using Protein G-Sepharose 
(Pharmacia). 
2.3. Purification of a@1 from HT-1080 cells 
HT-1080 fibrosarcoma cells were obtained from the European Col- 
lection of Animal Cell Cultures (Porton Down, UK) and were grown 
to confluence in 225 cm’ flasks (Costar). Cells (from 100 flasks) were 
detached with 3 mM EDTA in HBSS (GIBCO-BRL), washed with PBS 
and extracted with 40 ml of 2% (w/v) Triton X-100,5 mg/ml BSA, 150 
mM NaCl, 1 mM CaCl,. 1 mM MgCl,, 2 mM phenvlmethvlsulohonvl 
fluoride, 10 ,@ml leupeptin, 25 mM Tris-HC[ pH_7.4, on ice-for 30 
min. /31 integrins were purified from these extracts by mAb 13 affinity 
chromatography, essentially as previously described for the purification 
of/?1 integrins from lymphocytes [14]. Pooled fractions were then mixed 
with 2 ml mAb 16 Sepharose (5 mg IgG/ml Sepharose) for 2 h at room 
temperature. The suspension was then packed into a O.&cm diameter 
column and washed with 20 ml of 0.1% (w/v) Triton X-100, 150 mM 
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NaCl, 1 mM CaCI,, 1 mM MgC&, 25 mM Tris-HCl, pH 7.4. Bound 
material was &ted with 0.1% (w/v) Triton X-100, 1 mM CaCl,, I mM 
MgCI,, 10 mM NaOAc, pH 3.5, and 0.5 ml fractions were collected and 
neutralised with 0.1 ml of 1 M Tris-HCl, pH 8.2. 50-/J aliquots were 
analysed by SDS-PAGE using a 7.5% non-reducing resolving gel. 
The only bands detected by Coomassie Blue staining were those corre- 
sponding to expected positions of the a5 and bl subunits, and a5 and 
PI were the only integrin subunits detected in the eluted fractions by 
ELISA. 
2.4. Solid phase ussq 
Solid-phase ligandlreceptor binding was performed by a modifica- 
tion of the method of Charo and co-workers f151. 80-kDa CCBD 
fragment of fibronectin (500 ,ug/ml in PBS) was mixed with an equal 
mass of sulfa-N-hydroxysuccinimido biotin (Pierce, Chester, UK) and 
rotary mixed for 3040 min at room temperature. The mixture was then 
dialysed against several changes of 150 mM NaCl, 25 mM Tris-HCI, 
pH 7.4 to remove excess biotin. Purified a5gl integrin (at a concentra- 
tion of - 100 &ml) was diluted 1: 100 with PBS containing divalent 
cations, and 100,ul aliquots were added to the wells of a 96-well ELISA 
plate (Dynatech Immulon 3). Plates were incubated overnight at room 
temperature and wells were blocked for l-3 h with 200 ~1 of 5% (w/v) 
BSA, 150 mM NaCI, 0.05% (w/v) NaN,, 25 mM Tris-HC1, pH 7.4. 
Wells were then washed three times with 200~1 of 150 mM NaCl, I mM 
MnCI,, 25 mM Tris-HCI, pH 7.4, containing 1 mg/ml BSA (buffer A), 
and 100-/J aliquots of biotinylated CCBD fragment (-0.01 /@ml) di- 
luted in buffer A were added, with or without mAbs. The plate was then 
incubated at 30 “C for 3 h. Biotinylated ligand was aspirated and the 
wells washed three times with buffer A. Bound ligand was quantitated 
by addition of 1: 200 ExtrAvidin-peroxidase conjugate (Sigma) in 
buffer A for 10 min. Wells were then washed four times with buffer A, 
and colour was developed using ABTS (Sigma). Measurements ob- 
tained were the mean ? SD. of six replicate wells. The amount of 
non-specific binding was measured by determining the level of ligand 
binding to wells coated with BSA alone; these values were subtracted 
from the corresponding values for receptor-coated wells. 
2.5. Competitive ELISA experiments 
12GlO IgG was biotinylated as described above for the CCBD fi- 
bronectin fragment. ELISA plates were coated with purified a5pl and 
blocked as described above. Wells were then washed three times with 
buffer A. Biotinylated 12G10 (0.2 pug/ml in buffer A) was added to the 
wells in the absence or presence of excess unlabelled mAbs. The concen- 
tration of competitor antibodies was 20 /g/ml for purified IgG, ascites 
was used at 1 : 500 dilution. The plate was then incubated at room 
temperature for l-2 h. Unbound antibodies were aspirated and the 
wells washed three times with buffer A. Bound biotinylated antibody 
was quantitated by addition of 1: 500 ExtrAvadin-peroxidase in buffer 
A. Wells were then washed four times with buffer A, and colour was 
developed using ABTS substrate. Measurements obtained were the 
mean f S.D. of six replicate wells. The amount of non-specific binding 
was measured by determining the level of biotinylated antibody binding 
to wells coated with BSA alone. These values were subtracted from the 
corresponding values for receptor-coated wells. 
2.6. E~@Y of ligunds on the binding of mAbs to a5jIl 
ELISA plates were coated with purified cc5gl and blocked as de- 
scribed above. Wells were then washed three times with buffer A. 100~~1 
aliquots of mAbs (5 pg/ml or 1: 1000 dilution of ascites) in buffer A 
were added to the wells in the presence or absence of CCBD fragment 
(1 &ml) or GRGDS (5 pglml); a recombinant fragment of fibronectin 
(H/120) lacking the CCBD (1 /&ml), and GRDGS peptide (5 pg/ml) 
were used as controls. The plate was then incubated at room tempera- 
ture for 90 min. Unbound antibody was aspirated and the wells washed 
three times with buffer A. Bound antibody was quantitated by addition 
of 1 : 1000 anti-mouse peroxidase or anti-rat peroxidase conjugate in 
buffer A. Wells were then washed four times with buffer A, and colour 
was developed using ABTS substrate. Measurements obtained were the 
mean t SD. of four replicate wells. The amount of non-specific bind- 
ing was measured by determining the level of antibody binding to wells 
coated with BSA alone. These values were subtracted from the corre- 
sponding values for receptor-coated wells. 
To analyse the effect of RGD peptides on the apparent affinity of 
12GlO or 8A2 binding to as/St, the same procedures as described above 
were used, except that antibody binding was measured for a range of 
antibody concentrations in the presence of either GRGDS, or the con- 
trol peptide GRDGS. Non-linear regression analysis to estimate appar- 
ent affinity (l/K,) and the maximal level of binding was performed as 
previously described [14]. 
3. Results 
3.1. 12GlO is a novel uctivuting anti-p1 monoclonal antibody 
Hybridomas produced by immunising mice with j31 integrins 
from HT-1080 fibrosarcoma cells were screened by Western 
blotting to identify those that reacted with the j?l subunit. 
Several clones were found to recognise /Il, including one desig- 
nated 12GlO (result not shown). 12GlO and other previously 
described anti-/I1 mAbs were then tested for their effect on 
ligand binding to a@1 in a solid phase assay (Fig. 1). The 
results showed that the antibodies could be grouped into three 
classes: those that enhanced ligand binding (12G10, TS2/16 and 
8A2); those that had no significant effect on ligand binding 
(JBlB and K20); and those that inhibited ligand binding (13). 
TS2/16 and 8A2 have been previously shown to enhance 
cell adhesion by activating /31 integrins [16-181, whereas 13 
has been shown to inhibit pl integrin-ligand interactions [8]. 
Based on these results, 12GlO appears to be a new mem- 
ber of the subset of anti-/?1 mAbs that can activate ligand 
binding. 
3.2. The 12GlO epitope overlaps with that of other activating 
mAbs 
To investigate if the epitope recognised by 12GlO overlaps 
with that of the previously described activating mAbs, we stud- 
ied the ability of other anti-/R mAbs to competitively inhibit 
the binding of 12GlO to cxS/?l (Fig. 2). As expected, the binding 
of biotinylated 12GlO was strongly inhibited by unlabelled 
12GlO; in addition, 8A2 and TS2/16 completely inhibited 
12GlO binding, suggesting that these antibodies recognise the 
same, or closely overlapping epitopes on the/?1 subunit. 12GlO 
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Fig. 1. Effect of anti-/Y1 mAbs on the binding of CCBD fibronectin 
fragment to integrin a5gl in a solid phase assay. Binding of biotinylated 
CCBD fragment was detected as described in section 2. Results are 
expressed as % of control binding (in the absence of mAbs). 
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Fig. 2. Effect of anti-B1 mAbs on the binding of biotinylated 12GlO to 
integrin a5gl_in a competitive ELISA assay. Binding of biotinylated 
antibody, in the absence or presence of a large excess of competing 
unlabelled antibodies, was detected as described in section 2. Results 
are expressed as the % of control binding (in the absence of unlabelled 
antibodies). 
binding was also inhibited by mAb 13, although to a slightly 
lesser extent than 8A2 and TS2/16. Other antibodies, such as 
JBl B and K20, did not block 12GlO binding. It has been shown 
that 8A2, TS2/16 and 13 all recognise a small sub-region of 
the pl subunit (residues 207-218) [19]. Hence it appears that 
12GlO binds at, or very close to, this same region of the j?l 
subunit. 
3.3. 12GlO recognises a ligand-induced binding site 
To investigate if the binding of any of the anti-j?1 mAbs could 
be modulated by ligands, we measured the amount of antibody 
binding to a.S/?l in the presence of a CCBD fragment of fi- 
bronectin, or GRGDS peptide. A recombinant fragment of 
fibronectin lacking the CCBD, and GRDGS peptide were used 
as controls. The results (Table 1) showed that 12GlO binding 
was increased approximately 1.5-fold in the presence of ligands, 
whereas binding of the other activating antibodies was unaf- 
fected. Binding of the inhibitory mAb 13 was slightly decreased 
by ligands in this assay. 
Comparison of the effects of RGD peptide on 12GlO and 
8A2 binding to a5pl (Fig. 3A and 3B, respectively) demon- 
strated that ligand increased both the apparent affinity and the 
maximal level of 12GlO binding. In contrast, although the ap- 
parent affinity of 8A2 binding was increased by ligand, the 
maximal level of binding was unchanged. 
4. Discussion 
Our results show that 12G10 is a novel member of a family 
of anti-integrin mAbs known as anti-LIBS antibodies [4,5]. The 
epitopes recognised by this group of mAbs are expressed on a 
greater proportion of receptors in the ligand-occupied state 
than in the unoccupied state. All of the previously described 
anti-LIBS antibodies are against either the 83 integrin aIIb/?3 
[4,5] or theg2 integrin aMp2 [20]; this report is the first descrip- 
tion of this type of antibody for a pl integrin. 
Interestingly, none of the previously described anti-LIBS an- 
tibodies against aIIbp3 showed increased binding to crIIb/33 in 
the presence of GRGDS peptide in solid phase assays [4], 
whereas this peptide did increase 12GlO binding to a5/?1 in 
solid phase assays. The as/31 solid phase assay also has the 
useful property that ligand binding can be readily modulated 
by different mAbs. These features make it a potentially valuable 
aid for identifying the regions of the a5 and pl subunits that 
are involved in regulating ligand binding. 
Based on their observation that showed that the affinity of 
8A2 binding to a5pl on K562 cells was - 2-fold higher in the 
presence of GRGDSP peptide than in its absence, Faull and 
co-workers [21] proposed that 8A2 may be an anti-LIBS anti- 
body. However, in the above study, the maximal amount of 
8A2 bound (at saturating antibody concentrations) was not 
significantly altered by this peptide. In our assays the maximal 
level of 8A2 binding to as/?1 was also unaffected by ligands. By 
definition, for a true anti-LIBS mAb the maximal amount of 
bound antibody should be increased in the presence of ligands 
[4,5], suggesting that 8A2 is not a genuine member of this class 
of antibodies. 
None of the anti-LIBS antibodies so far described inhibit the 
binding of primary ligand, however, several of these antibodies 
(including 12GlO) markedly increase the affinity of ligand bind- 
ing. It has been proposed that polypeptides may exist in confor- 
mational equilibria and that addition of an antibody specific for 
one conformation may shift the equilibrium in favour of that 
conformation [22]. Hence, it has been suggested that some 
anti-LIBS mAbs increase the affinity of binding by shifting the 
conformational equilibrium between inactivated and activated 
states of the integrin in favour of the activated state [5]. Activat- 
ing mAbs that do not recognise a LIBS epitope (such as 8A2) 
nevertheless show an increased affinity of binding to the ligand- 
occupied form of the integrin, and may therefore stabilise this 
conformation. 
8A2, TS2/16 (and other previously described activating 
mAbs) have been shown to recognise a small region of the j?l 
Table 1 
Effect of ligands on the binding of anti-b1 mAbs to integrin as/?1 
Ligand % Control binding 
12GlO 8A2 TS2/16 13 
CCBD fragment 146* 96 103 92** 
H/120 98 100 91 99 
GRGDS 160* 102 96 91** 
GRDGS 99 106 99 96 
Antibody binding was detected as described in section 2, in the presence 
or absence of authentic (CCBD fragment or GRGDS) or control (H/ 
120 or GRDGS) ligands. Antibody concentrations (5 &ml or 1: 1000 
dilution of ascites) were chosen to give near maximal binding. Results 
are expressed as the % of antibody binding in the absence of ligands. 
In this assay, the absolute level of 12GlO binding in the presence of 
ligands (A,,, = 1.1) was similar to the level of 8A2 or TS2/16 binding 
with or without ligands (A,,, = 1.1). All standard deviations were < 4% 
of control binding. Statistical significance of difference from binding in 
the absence of ligands was evaluated using Student’s t-test: *P < 0.001; 
**P < 0.05. In other experiments (not shown) the binding of antibodies 
JBlB and K20 was unaffected by ligands. 
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Fig. 3. Effect or RGD peptide ligand on the apparent affinity of binding 
of mAbs 12GlO (A) and 8A2 (B) to a5/31. Antibody binding was 
measured in the presence of GRGDS (0) or the control peptide 
GRDGS (0). By non-linear regression analysis, the apparent affinity 
of 12GlO binding is increased approx. 2-fold, and the maximal level of 
binding 1.4-fold, in the presence of ligand. The apparent affinity of 8A2 
binding is increased approx. 1.6-fold in the presence of ligand but the 
maximal level is not significantly changed. 
subunit (residues 207-218) that lies between two sequences 
implicated in ligand recognition [19]. Intriguingly, the same 
region of thepl subunit also contains the epitopes of inhibitory 
mAbs such as 13 [19]. Using competitive ELISA experiments, 
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we found that 12GlO binds at, very close to, this region of the 
/I1 subunit. While we cannot rule out the possibility that 8A2 
and TS2/16 may cause a conformational change that greatly 
reduces the affinity of 12GlO binding, the essentially complete 
inhibition of 12GlO binding by these antibodies strongly sug- 
gests that the epitopes recognised by 8A2 and TS2/16 are 
closely overlapping with the 12G 10 epitope. However, exposure 
of the 8A2 and TS2/16 epitopes is unaffected by ligand occu- 
pancy. The increase in 12GlO binding to pl caused by ligands 
nevertheless demonstrates that the conformation of this part of 
the fil subunit is significantly altered by ligand recognition, 
leading to increased exposure of certain epitopes. To shed fur- 
ther light on the role of this region of the /I1 subunit in integrin 
regulation, it will be important in the future to identify the 
precise sequence in the /I1 subunit that contains the 12GlO 
epitope, and to compare this with the sequences recognised by 
other activating mAbs. 
In summary, we have described a novel activating anti+1 
integrin monoclonal antibody that reacts preferentially with 
the ligand-occupied form of cx5/0. The epitope recognised 
by this antibody is located at, or very near to, a previous- 
ly defined sub-region of the pl subunit that appears to have 
a crucial role in regulating integrin activity. If, as predict- 
ed, this regulatory region forms part of an A-domain-like 
structure [23], the epitope recognised by 12GlO may be 
spatially close to a site involved in both ligand and cation 
binding. 
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